Table 2.

Baseline characteristics of the registry data groups



Nontransplantation

Transplantation

Statistical differences
Characteristic
MDS IMRAW
MDS IBMTR
MDS FHCRC
AML IBMTR
P*
P
P
No. of patients   184   193   67   230     
Age, y, median (range)   49.8 (18-60)   39.4 (18-59)   45.6 (20-60)   41.7 (18-60)   <.0001   <.0001   NS  
Male sex, %   58.2   53.4   59.7   53.5   NS   NS   NS  
FAB subtype, %      <.0001   NS   NA  
RA   51.6   30.57   38.81   NA     
RARS   16.9   2.07   4.48   NA     
RAEB   25.0   28.5   37.31   NA     
RAEB-t   6.5   34.72   17.91   NA     
Unknown   0   4.15   1.49   NA     
IPSS risk group, %      <.0001   <.001   NA  
Low   31.0   9.84   2.99   NA     
Int-1   42.9   53.37   32.84   NA     
Int-2   20.1   17.62   46.27   NA     
High
 
6.0
 
19.17
 
17.91
 
NA
 

 

 

 


Nontransplantation

Transplantation

Statistical differences
Characteristic
MDS IMRAW
MDS IBMTR
MDS FHCRC
AML IBMTR
P*
P
P
No. of patients   184   193   67   230     
Age, y, median (range)   49.8 (18-60)   39.4 (18-59)   45.6 (20-60)   41.7 (18-60)   <.0001   <.0001   NS  
Male sex, %   58.2   53.4   59.7   53.5   NS   NS   NS  
FAB subtype, %      <.0001   NS   NA  
RA   51.6   30.57   38.81   NA     
RARS   16.9   2.07   4.48   NA     
RAEB   25.0   28.5   37.31   NA     
RAEB-t   6.5   34.72   17.91   NA     
Unknown   0   4.15   1.49   NA     
IPSS risk group, %      <.0001   <.001   NA  
Low   31.0   9.84   2.99   NA     
Int-1   42.9   53.37   32.84   NA     
Int-2   20.1   17.62   46.27   NA     
High
 
6.0
 
19.17
 
17.91
 
NA
 

 

 

 

MDS indicates myelodysplastic syndrome; AML, acute myelogenous leukemia; Tx, transplant; FAB, French-American-British Classification of Myelodysplastic Syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; IMRAW, International MDS Risk Assessment Workshop; IBMTR, International Bone Marrow Transplant Registry; FHCRC, Fred Hutchison Cancer Research Center; NS, not significant; and NA, not applicable.

*

Probability of testing MDS IMRAW versus all transplantations.

Probability of testing MDS IBMTR versus MDS FHCRC.

Probability of testing MDS versus AML transplantation.